Interleukin Genetics commences two new PST test clinical studies in China

Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that the Company has initiated two clinical studies to demonstrate the utility of its new PST^® genetic test in the ethnic Chinese population. The programs are being conducted in collaboration with Professor Chi-Cheng Tsai of Kaohsiung Medical University and Professor Dong Chen at Shanghai Stomatological Disease Center.  

"We are pleased to have initiated these two studies with our collaborators in China.  Demonstration of the utility of the PST in Asian populations will be important for expanding the use of our test," said Lewis H. Bender, Chief Executive Officer of Interleukin Genetics. "Further, we believe that the ongoing clinical study of our PST test being conducted by the University of Michigan has the potential to make a major impact on improving oral health care in the U.S."

In addition, the Company announced today that Chief Scientific Officer Dr. Kenneth Kornman will present "Impact of Risk Assessment on Diagnosis and Management of Periodontal Disease" on November 15 at the 2011 American Academy of Periodontology's Annual Meeting in Miami. Dr. Kornman will also present "Risk Factors for Recurrent Periodontitis" at the Harvard University School of Dental Medicine on November 30.

"Presenting improved methods to manage patients using diagnostic and prognostic technologies to the dental and periodontal community is important to advancing the science in this field," said Dr. Kornman. "We are working with key academic opinion leaders to introduce the benefits of using these new tools."